J&J turns its back on Capri­cor and its failed stem cell tech, tak­ing its mon­ey and rep with it

A lit­tle more than three years ago, J&J stepped up with a $12.5 mil­lion up­front to rent a front row seat on Capri­cor Ther­a­peu­tics’ $CAPR Phase II stem cell study, look­ing to see if their off-the-shelf ap­proach could mend a dam­aged heart. At the time, CEO Lin­da Mar­bán told me that it was well worth the year-long re­view ef­fort need­ed to bring the phar­ma gi­ant to the ta­ble, look­ing to roll ahead with $325 mil­lion in mile­stones.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.